Aura Biosciences, Inc.
AURA
Last
$6.54
Day
+0.5%
1y
+7.9%
5y
-56.0%
52w
-31.8%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1232d
EMA 21
6.48
EMA 50
6.79
EMA 200
6.80
20d high
-9.1%
5y high
-75.1%
5y range
10th
Positions held
Your positionsAURA isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-3
Hold
watch
Signal
Neutral
Target
$6.99
Stop
$6.10
Stop distance
6.7%
Target vs last
+6.9%
Fundamentals
| Market cap | $674.60M | Enterprise value | $367.35M | Trailing P/E | — | Forward P/E | -3.20 |
| PEG | — | Price / book | 2.13 | Beta | 0.41 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -53.5% | ROA | -31.2% | Debt / equity | 0.05 |
| Current ratio | 16.82 | Free cash flow | -$56.32M | Analyst recommendation | none | Mean target | $16.60 |
| 52w high | $9.54 | 52w low | $4.73 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$45.6M | -$33.7M | -$25.6M | -$26.1M | -$27.0M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$48.1M | -$34.9M | -$27.2M | -$27.9M | -$28.6M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$106M | -$86.9M | -$76.4M | -$58.8M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$113M | -$96.1M | -$85.0M | -$60.3M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-06 · Is Aura Investments (TASE:AURA) Fully Valued As Mixed Earnings And A New Dividend Stir Interest?
2026-09-02 · Aura Biosciences to Participate in Upcoming Investor Conference
2026-09-01 · Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-08-11 · Aura Biosciences Q2 Loss Widens
2026-08-11 · Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Price (daily)
Full chart · RSI · MACD · patternsAURA · daily+2.3% over 14 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin